참고문헌
- Haam SJ, Lee DY, Paik HC. An overview of lung transplantation in Korea. Transplant Proc 2008;40(8):2620-2. https://doi.org/10.1016/j.transproceed.2008.07.114
- Ministry of Health & Welfare, KONOS. 2014 KONOS Annual Report 2014.
- Synder LD and Palmer SM. Immune mechanisms of lung allograft rejection. Semin Respir Crit Care Med 2006;27(5):534-43. https://doi.org/10.1055/s-2006-954610
- Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005;43 (Suppl1): S49-58. https://doi.org/10.1080/13693780400020113
- Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32(3):358-66. https://doi.org/10.1086/318483
- Husain S, Kwak EJ, Obman A, et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004;4(5): 796-802. https://doi.org/10.1111/j.1600-6143.2004.00415.x
- Shitrit D, Ollech JE, Ollech A, et al. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. J Heart Lung Transplant 2005;24(12):2148-52. https://doi.org/10.1016/j.healun.2005.05.003
- Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46(3):327-60. https://doi.org/10.1086/525258
- Segal BH. Aspergillosis. N Engl J Med 2009;360(18):1870-84. https://doi.org/10.1056/NEJMra0808853
- Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6):408-15. https://doi.org/10.1056/NEJMoa020191
- He SY, Makhzoumi ZH, Singer JP, et al. Practice variation in Aspergillus prophylaxis and treatment among lung transplant centers: a national survey. Transpl Infect Dis 2015;17(1):14-20. https://doi.org/10.1111/tid.12337
- Zonios DI and Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med 2008;29(2):198-210. https://doi.org/10.1055/s-2008-1063858
- Snell GI, Westall GP, Paraskeva MA. Immunosuppression and allograft rejection following lung transplantation: evidence to date. Drugs 2013;73(16):1793-813. https://doi.org/10.1007/s40265-013-0136-x
- Chiang CY, Schneider HG, Levvey B, et al. Tacrolimus Level Variability Is a Novel Measure Associated with Increased Acute Rejection in Lung Transplant (LTx) Recipients. J Heart Lung Transplant; 32(4):S170.
- Pollock-Barziv SM, Finkelstein Y, Manlhiot C, et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr Transplant 2010;14(8):968-75. https://doi.org/10.1111/j.1399-3046.2010.01409.x
- van Gelder T. Drug interactions with tacrolimus. Drug Saf 2002; 25(10):707-12. https://doi.org/10.2165/00002018-200225100-00003
- Billaud EM, Guillemain R, Berge M, et al. Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients. Med Mycol 2010;48 (Suppl1): S52-9. https://doi.org/10.3109/13693786.2010.505203
- Singh N, Husain S, the ASTIDCoP. Invasive Aspergillosis in Solid Organ Transplant Recipients. Am J Transplant 2009;9:S180-91. https://doi.org/10.1111/j.1600-6143.2009.02910.x
- J.M. Morton, L.M. Kear, S. Williamson, et al. Trough levels are inadequate for monitoring tacrolimus pharmacokinetics in lung transplantation. J Heart Lung Transplant 2002;21(1):144.
- Pfizer Roerig. Prescribing information. Vfend (voriconazole). Available from http://http://labeling.pfizer.com/ShowLabeling.aspx?id=618#section-7. Accessed November 7, 2015.
- Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy 2010; 30(8):842-54. https://doi.org/10.1592/phco.30.8.842
- Capone D, Tarantino G, Gentile A, et al. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient. J Clin Pharm Ther 2010;35(1):121-4. https://doi.org/10.1111/j.1365-2710.2009.01070.x
- Venkataramanan R, Zang S, Gayowski T, et al. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002;46(9): 3091-3. https://doi.org/10.1128/AAC.46.9.3091-3093.2002
- Mori T, Kato J, Yamane A, et al. Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation. Int J Hematol 2012;95(5):564-9. https://doi.org/10.1007/s12185-012-1057-2
- Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006;26(12):1730-44. https://doi.org/10.1592/phco.26.12.1730
- Antiviral drugs advisory committee, F D A. Briefing Document for Voriconazole(Oral and Intravenous Formulations). Silver Spring MD: US Food and Drug Administration; 2001.
- Ministry of Food and Drug Safety. Association Study Between Drugmetabolizing Enzyme Genotype and Pharmacokinetics. 2010.
- Astellas Pharma US I. Prescribing information of Prograf (tacrolimus). Available from http://www.astellas.us/docs/prograf.pdf. Accessed November 21, 2015.